Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-28
2007-08-28
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S226000, C546S210000, C546S316000, C548S240000, C548S250000, C548S335100, C548S470000, C549S074000, C564S152000, C514S378000, C514S416000, C514S588000, C514S616000
Reexamination Certificate
active
10427106
ABSTRACT:
The present invention relates to compounds of formula (I):useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4864017 (1989-09-01), Thaisrivongs et al.
patent: 5142056 (1992-08-01), Kempf et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5387742 (1995-02-01), Cordell et al.
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5475138 (1995-12-01), Pal et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5631405 (1997-05-01), Pal et al.
patent: 5663200 (1997-09-01), Bold et al.
patent: 5708004 (1998-01-01), Talley et al.
patent: 5720936 (1998-02-01), Wadsworth et al.
patent: 5721130 (1998-02-01), Seubert et al.
patent: 5744346 (1998-04-01), Chrysler et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5807891 (1998-09-01), Bold et al.
patent: 5811633 (1998-09-01), Wadsworth et al.
patent: 5850003 (1998-12-01), McLonlogue et al.
patent: 5877015 (1999-03-01), Hardy et al.
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 5912410 (1999-06-01), Cordell et al.
patent: 5942400 (1999-08-01), Anderson et al.
patent: 5976894 (1999-11-01), Dolle, III et al.
patent: 5994398 (1999-11-01), John et al.
patent: 6045829 (2000-04-01), Liversidge et al.
patent: 6060476 (2000-05-01), Vazquez et al.
patent: 6136824 (2000-10-01), MacLeod et al.
patent: 6191166 (2001-02-01), Audia et al.
patent: 6191277 (2001-02-01), Dolle et al.
patent: 6613764 (2003-09-01), Randad et al.
patent: 2003/0125365 (2003-07-01), Fisher et al.
patent: 4003575 (1991-08-01), None
patent: 0 609 625 (1994-08-01), None
patent: 2000290242 (2000-10-01), None
patent: 98/22597 (1998-05-01), None
patent: 98/33795 (1998-08-01), None
patent: 99/41266 (1999-08-01), None
patent: 99/64001 (1999-12-01), None
patent: 00/03819 (2000-01-01), None
patent: 00/17369 (2000-03-01), None
patent: 00/47618 (2000-08-01), None
patent: WO 00/56335 (2000-09-01), None
patent: 00/71101 (2000-11-01), None
patent: 01/10387 (2001-02-01), None
patent: 01/23533 (2001-04-01), None
patent: WO 03/029169 (2003-04-01), None
Cavallaro, C. et al.: Allylindium and allylboronic acid pinacolate : Application to the solid-phase synthesis of hydroxypropylamines. Tetrahed. Lett. vol. 40, pp. 2711-2714, 1999.
Y. Gopichand et al.,Tetrahedron Ltrs. (1979) 49:3921-3924.
R. Rohringer et al.,Tetrahedron Ltrs. (1969) 33:2807-2810.
E. Takashiro, et al.,Bioorganic & Medicinal Chem. (1999) 7:2105-2114.
C.M. Tice, et al.,J. Org. Chem. (1983) 48:5043-5048.
International Search Report for International Application PCT/US 03/13462.
Benedetti et al., “Stereoselective synthesis of non symmetric dihydroxyethylene dipeptide isosteres via epoxyalcohols derived from α-amino acids,”Bioorg. Med. Chem. Lett. 9:3027-3030 (1999).
Citron et al., “Mutation of the β -amyloid precursor protein in familial Alzheimer's disease increases β -protein production,”Nature360:672-674 (1992).
Database Crossfire BEILSTEIN Online Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE (Database accession No. BRN 5926098) XP002228494 Abstract.
Dantzig et al., “Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979”Cancer Research, 56, 4171-4179 (1996).
Emilien et al., “Prospects for Pharmacological Intervention in Alzheimer Disease,”Arch. Neurol.57:454-459 (2000).
Games et al., “Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein,”Nature373:523-527 (1995).
Ghosh et al., “Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylgylcines as Novel P2-Ligands and Pyrazine Amides as P3-Ligands,”J. Med. Chem.36:2300-2310 (1993).
Hardy et al., “Framing β-amyloid,”Nature Genet.1:233-234 (1992).
Hussain et al., “Identification of a Novel Aspartic Protease (Asp 2) as β -Sedretase,”Molecular and Celluar Neuroscience14:419-427 (1999).
Hyafil et al., “In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative,”Cancer Research, 53, 4595-4602 (1993).
Kang et al., “The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor,”Nature325:733-736 (1987).
Kitaguchi et. al., “Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity,”Nature331:530-532 (1988).
Lin et al., “Human aspartic protease memapsin 2 cleaves the β-secretase site of β -amyolid precursor protein,”PNAS USA97:1456-1460 (2000).
Luo et al., “Mice deficient in BACE 1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation,”Nature Neuroscience4:231-232 (2001).
Pirttila et al., “Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease,”Neuroscience Letter249:21-24 (1998).
Reid et al., “A Novel Bicyclic Enzyme Inhibitor as a Consensus Peptidomimetic for the Receptor-Bound Conformations of 12 Peptidic Inhibitors of HIV-1 Protease,”J. Am. Chem. Soc.118:8511-8517 (1996).
S. H. Rosenberg et al., “Novel Renin Inhibitors Containing Analogues of Statine Retro-Inverterd at the C-Termini: Specificity at the P2 Histitine Site,”J. Med. Chem.30, 7:1224-1228 (1987).
Sabbagh, M. et al., “β -Amyloid and Treatment Opportunities for Alzheimer's Disease,”Alz. Dis. Rev.3:1-19 (1997).
Sawyer et al., “Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties,”Bioorg. Med. Chem. Lett.1993, 3, 819-824.
Selkoe et al., “The Molecular Pathology of Alzheimer's Disease,”Neuron6:487-498 (1991).
Seubert et al., “Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids,”Nature359:325-327 (1992).
Sinha et al., “Purification and cloning of amyloid precursor protein β-secretase from human brain,”Nature402:537-540 (1999).
Thaisrivongs et al., “Renin Inhibitors. Design of Angiotensinogen Transistion-State Analogues Containing Novel (2R,3R,4R,5S)-5-Amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic Acid,”J. Med. Chem.30: 976-982 (1987).
Thaisrivongs et al., “Inhibitors of the Protease from Human Immunodeficiency Virus: Design and Modeling of a Compound Containing a Dihydroxyethylene Isostere Insert with High Binding Affinity and Effective Antiviral Activity,”J. Med. Chem.34: 2344-2356 (1991).
Thaisrivongs et al., “Inhibitors of the Protease from Human Immunodeficiency Virus: Synthesis, Enzyme Inhibition, and Antiviral Activity of a Series of Compounds Containing the Dihydroxyethylene Transition-State Isoster,”J. Med. Chem.36: 941-952 (1993).
Vassar et al., “β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE,”Science286: 735-741 (1999).
Witherspoon et al., “Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918,”Clin. Cancer Res., 2, 7-12 (1996).
Yan et al., “Membrane-anchored aspartyl with Alzheimer's disease β-secretase activity,”Nature402:533-537 (1999).
Beck James P.
Brogley Louis
Jacobs Jon S.
John Varghese
Pulley Shon R.
Aulakh Charanjit S.
Elan Pharmaceuticals Inc.
McDonnell Boehnen & Hulbert & Berghoff LLP
Pharmacia & Upjohn Company
LandOfFree
Hydroxypropyl amides for the treatment of Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxypropyl amides for the treatment of Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxypropyl amides for the treatment of Alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3833045